摘要
采用发色底物法检测６１例视网膜静脉阻塞（ＲＶＯ）患者血浆组织纤溶酶原激活剂（ｔ－ＰＡ）及纤溶酶原激活剂抑制物（ＰＡＩ）活性。正常对照组ｔ－ｐＡ活性２．０７±０．４０ＩＵ／ｍｌ，ＰＡＩ活性７．３３±０．６７ＡＵ／ｍｌ。ＲＶＯ患者ｔ－ＰＡ活性显著降低（１．６９±０．５６ＩＵ／ｍｌ，ｐ＜０．０１），ＰＡＩ活性显著增高（８．８０±１．６０ＡＵ／ｍｌ，Ｐ＜０．０１）。其中缺血型较非缺血型ｔ－ｐＡ活性更低（分别为１．３５±０．４３ＩＵ／ｍｌ，１．９２±０．５３ＩＵ／ｍｌ，Ｐ＜０．０１），ＰＡＩ活性更高（分别为９．３５±１．３７ＩＵ／ｍｌ，８．４２±１．２９ＩＵ／ｍｌ，Ｐ＜０．０１）．并且，这些改变随病情严重程度的加重而愈显著。
The activlties of
tissue type plasminogen activator(t-pA)and plasminogen activator inhibitor(PAI)in plasm from 6
1 patients with retinal vein occlusion(RVO)were measured by usingchromatogenous substrate
s-2390 assay,The results showed that the t-PA activity in the patients withRVO were
decreased(1.69±0.56IU/ml,P<0.01)and PAI activity increased(8.80±
1.60AU/ml,P<0.01)comparing with health subjects 2.07±0. 40IU/ml and 7.33±
0.67AU/mlrespectively,Among the patients,t- PA activity in the patients with ischemic
retinopathy was moreobviously decreased(1.35±0.43IU/ml,P<0.01)and the activity of PAI was
increased(9.35±1.3 7AU/ml)comparing with those petients suffering from noruschemic
retinopathy(the activities oft-PA and PAI were 1.92±0.53IU/ml and 8.42±1.29AU/ ml
respectively,P<0.01).Inadd i tion,these changes were getting more obvious with the degree of
severity of the disease,Theseresul ts indicated that there was disorder in the balance between
t- pA and PAI in patients wi th RVO,which may play an important role in the course of occurrence
and development of RVO,especial ly inischemic type.
出处
《中华眼底病杂志》
CAS
CSCD
1994年第2期71-73,共3页
Chinese Journal of Ocular Fundus Diseases
关键词
视网膜
静脉阻塞
纤溶酶原
激活剂
retinal vein occlusion
tissue-type plasminogen activator plasminogen activator inhlbitor
